🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with figures suggesting in excess of 82 million infections annually. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the reality of rising global incidence, the spread of superbugs and the highly restricted available drugs at this time.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Secure Clearance

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Experts hope that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone represents a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Global Access

Based on data released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves a dual-drug approach. The trial involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced hope. The availability of a easy-to-administer therapy such as this is described as a "game-changer" for public health efforts. This is deemed crucial to reduce the burden of the illness for patients and to prevent the spread of extremely resistant gonorrhoea around the world.